Revolution MedicinesRVMD
RVMD
About: Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Employees: 490
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
120% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 25
44% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 63
16% more capital invested
Capital invested by funds: $6.62B [Q2] → $7.66B (+$1.04B) [Q3]
14% more funds holding
Funds holding: 221 [Q2] → 251 (+30) [Q3]
6% more funds holding in top 10
Funds holding in top 10: 18 [Q2] → 19 (+1) [Q3]
2.29% less ownership
Funds ownership: 103.4% [Q2] → 101.12% (-2.29%) [Q3]
58% less call options, than puts
Call options by funds: $11.8M | Put options by funds: $28.1M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
36%
upside
Avg. target
$70
59%
upside
High target
$87
97%
upside
9 analyst ratings
9 positive
100%
0 neutral
0%
0 negative
0%
Wedbush Robert Driscoll 20% 1-year accuracy 13 / 65 met price target | 52%upside $67 | Outperform Maintained | 6 Dec 2024 |
Needham Ami Fadia 37% 1-year accuracy 57 / 154 met price target | 41%upside $62 | Buy Maintained | 6 Dec 2024 |
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target | 63%upside $72 | Buy Maintained | 4 Dec 2024 |
Guggenheim Michael Schmidt 26% 1-year accuracy 5 / 19 met price target | 97%upside $87 | Buy Maintained | 3 Dec 2024 |
JP Morgan Eric Joseph 48% 1-year accuracy 14 / 29 met price target | 61%upside $71 | Overweight Maintained | 3 Dec 2024 |
Financial journalist opinion
Based on 8 articles about RVMD published over the past 30 days
Positive
24/7 Wall Street
6 days ago
Insiders Are Loving These 6 Stocks Right Now
The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.
Neutral
GlobeNewsWire
2 weeks ago
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million
Neutral
Seeking Alpha
2 weeks ago
Revolution Medicines: Risky Buy On Recent Share Price Dip
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDAC, with potential expansion into NSCLC and CRC, positioning it as a potential new standard of care. Despite a recent stock dip due to a $600m public offering, Revolution's robust cash position and promising pipeline offer significant long-term potential.
Positive
Benzinga
2 weeks ago
Top 3 Health Care Stocks That Could Blast Off In December
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
2 weeks ago
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are to be sold by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 2,445,652 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $750.0 million before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares and excluding the exercise of any pre-funded warrants. The offering is expected to close on December 5, 2024, subject to customary closing conditions.
Neutral
GlobeNewsWire
2 weeks ago
Revolution Medicines Announces Commencement of Public Offering of Common Stock
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
2 weeks ago
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial
Neutral
GlobeNewsWire
3 weeks ago
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.
Neutral
Seeking Alpha
1 month ago
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile
Charts implemented using Lightweight Charts™